Trial Profile

Proof-of-concept study of ficlatuzumab in combination with erlotinib in patients with advanced non-small cell lung cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Nov 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ficlatuzumab (Primary) ; Erlotinib
Indications Non-small cell lung cancer
Focus Biomarker; Proof of concept; Therapeutic Use
Sponsors AVEO Oncology; Biodesix

Most Recent Events

29 Sep 2014 This confirmatory trial is expected to be initiated by the end of 2014, according to a media release from AVEO Oncology and Biodesix.
16 Apr 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com